Tissue Diagnostics Market - Forecast(2024 - 2030)

Tissue Diagnostics Market Overview

The Tissue Diagnostics market size is estimated to reach $5.3 billion by 2026, growing at a CAGR of 5.7% during the forecast period 2021-2026. Tissue Diagnostics involves the removal and collection of tissue in order to be examined microscopically. A slide staining system is used in order to hold microscopic slides simultaneously for an efficient staining process. Tissue Diagnostics is essential in the identification of diseases such as cancer during its initial stages. Diseases such as breast cancer, gastric cancer, and prostate cancer can be diagnosed through In Situ Hybridization (ISH), Digital Pathology, and other technologies of Tissue Diagnostics. An increase in the use of automated tissue diagnostic systems for the purpose of diagnosing diseases is anticipated to drive the market during the forecast period. However, the high cost of tissue diagnostics is predicted to be a major challenge during the forecast period.

Report Coverage

The report: “Tissue Diagnostics Market Forecast (2021-2026)”, by Industry ARC, covers an in-depth analysis of the following segments of the Tissue Diagnostics Market.

By Product Type: Consumables and Instruments
By Technology: Immunohistochemistry (IHC), In Situ Hybridization (ISH), Digital Pathology & Workflow Management and Special Staining
By Application: Breast Cancer, Gastric Cancer, Non-small Cell Lung Cancer, Prostate Cancer, and Others.
By End User: Hospitals, Research Laboratories, Pharmaceutical Organizations and Contract Research Organizations (CROs)
By Geography: North America (U.S., Canada, and Mexico), Europe (Germany, UK, France, Italy, Spain, Russia, and Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Australia & New Zealand, and Rest of Asia-Pacific), South America (Brazil, Argentina, and Rest of South America) and Rest of World (Middle East and Africa). 

Key Takeaways

• Geographically, the North American Tissue Diagnostics market accounted for the largest share in 2020 owing to the presence of well-developed healthcare infrastructure and high levels of investments in the region. 
• An increase in the cases of cancers among the population is anticipated to drive the market. However, the lack of developed infrastructure necessary for Tissue Diagnostics in developing and underdeveloped regions is anticipated to hamper growth.
• Detailed analysis on the Strength, Weaknesses, and Opportunities of the prominent players operating in the market will be provided in the Tissue Diagnostics Report.

Tissue Diagnostics Market Segment Analysis - By Technology

Based on Technology, the Tissue Diagnostics Market is segmented into Immunohistochemistry (IHC), In Situ Hybridization (ISH), Digital Pathology & Workflow Management and Special Staining. The IHC segment is anticipated to have the largest share of the market in 2020 and is poised to dominate the market during the forecast period 2021-2026. This is attributed to its low costs and well-established presence. Moreover, both fresh and frozen tissue samples can be used in IHC. IHC has different tests that can help determine the origin of a tumor. This is not possible in other routine histology tests which makes IHC a more preferred choice. The Digital Pathology segment is projected to be the fastest-growing during the forecast period at a CAGR of 6.1% owing to the increase in the recent adoption of Whole Slide Imaging (WSI) in pathology. WSI refers to the scanning of conventional slides to produce digital slides. This is beneficial for diagnostic, educational, and research purposes.

Tissue Diagnostics Market Segment Analysis - By Application

The Tissue Diagnostics Market based on Application can be further segmented into Breast Cancer, Gastric Cancer, Non-small Cell Lung Cancer, Prostate Cancer and Others. The Breast Cancer segment dominated the market in 2020 owing to the global increase in breast cancer cases. For instance, it is estimated that 1 in 8 or 13% of women in the US will develop breast cancer during their lifetime. This has resulted in the increase in awareness of the importance of early detection and diagnosis of breast cancer which generates demand for Tissue Diagnostics systems. This high awareness has resulted in a decrease in deaths from breast cancer by 41% from 1989 to 2018. Currently, 63% of breast cancers in the US are diagnosed during the initial stages owing to the increase in screening for the disease. The Prostate Cancer segment is anticipated to grow the fastest at a CAGR of 5.9% owing to the increase in the global geriatric population and rise in demand for early detection and treatment of the disease.

Tissue Diagnostics Market Segment Analysis - By Geography

The Tissue Diagnostics Market based on Geography can be segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. The North American segment is projected to dominate the Tissue Diagnostics market during the forecast period 2021-2026 owing to the presence of highly developed healthcare infrastructure, favorable reimbursement policies for cancers, high patient awareness levels, and growing geriatric population. The high investments in the region for the development of innovative technologies for Tissue Diagnostics by governments as well as major private market players is another key factor for the growth of the market. However, the Asia Pacific region is projected to be the fastest-growing segment at a CAGR of 6.3% owing to the high population growth and increased cases of chronic illnesses in the region. Less stringent laws regarding air pollution in emerging economies such as China and India are resulting in an increase in lung cancer cases. This is predicted to further increase the demand for Tissue Diagnostics in Hospitals and Laboratories.

Tissue Diagnostics Market Drivers

Increase in Geriatric Population is Projected to Drive Market Growth

There were around 727 million persons over the age of 65 in 2020 and constituted 9.3% of the overall population. The geriatric population is predicted to reach 16% by 2050. This is anticipated to drive the market during the forecast period as the risk of cancer development significantly increases with age. The median age for diagnostics of breast cancer is 62 years while it is 71 years for lung cancer and 68 years for prostate cancer. This increase in the geriatric population generates the demand for Tissue Diagnostics as early diagnosis is the major factor that determines the chance of patient survival.

Rise in Worldwide Cancer Cases is Anticipated to Boost Product Demand

The rise in cases of cancer worldwide is a major factor driving the market during the forecast period. Cancer is one of the leading causes of death worldwide. According to the World Health Organization (WHO), cancer was responsible for around 10 million deaths in 2020. The most common cancers were breast, lung, colon & rectum, and prostate cancers. Cancer-related deaths are anticipated to further rise during the coming years and it is projected to reach 16.4 million by 2040. Moreover, around 70% of the deaths occurred in developing and underdeveloped regions. The rapid rise in income and increase in healthcare investments by major developing countries such as India, China, and Brazil is another key driver during the forecast period. 

Tissue Diagnostics Market Challenges

The High Cost of Tissue Diagnostics Equipment is Anticipated to Hamper Market Growth.

The high cost of some of the equipment necessary for Tissue Diagnostics is a major challenge to the demand. Its effect is more prominent in developing regions as their hospitals and laboratories do not have the financial capacity to purchase such expensive devices. Moreover, the time required to break even on the high investments is longer in developing regions as average treatment costs are around 1000 times lower than that of high-income countries such as the US. The lack of local manufacturers in the region also increases equipment costs as they have to be imported.

The Covid-19 Pandemic is Projected to Limit Growth Opportunities

The rapid spread of the Covid-19 virus and the increased influx of patients needing hospitalization have led to hospitals diverting funds and manpower from other departments in order to increase hospital beds, ICU units, ventilators, Oxygen cylinders, PPE kits, Testing kits, and other equipment essential for the treatment and diagnosis of Covid-19 patients. However, this has led to a decrease in funding of other departments which significantly impacts their ability to purchase or upgrade equipment. This is projected to reduce the demand for Tissue Diagnostics devices during the forecast period. Moreover, the fear of infection from healthcare facilities is discouraging patients from visiting hospitals or laboratories, thereby further decreasing the demand. 

Tissue Diagnostics Market Industry Outlook:

Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Tissue Diagnostics Market. Top 10 companies in of the industry include:

1. GE Healthcare
2. BioGenex
3. Histoline Laboratories
4. Abbott Laboratories
5. Thermo Fisher Scientific Inc.
6. Cell Signaling Technology Inc.
7. Cellpath Ltd
8. Biomeriux
9. Danaher
10. Roche

Partnerships/Product Launches:

• In January 2021, Roche launched two digital pathology image analysis algorithms called uPath HER2 (4B5) image analysis and uPath HER2 Dual ISH image analysis for precision patient diagnosis in breast cancer
• In April 2019, Hologic, Inc. announced that the ThinPrep Genesis processor for cytology slide and molecular test preparation had received a CE IVD mark in Europe. The new system is much more automated than the previous systems in use.

Relevant Links:

Professional Diagnostics Market – Forecast (2021 - 2026)

Report Code: HCR 80706

Cancer Diagnostics Market – Forecast (2021 - 2026)

Report Code: HCR 0195 

For more Lifesciences and Healthcare Market reports, please click here